Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

How to apply for vascepa's patient assistance?
Is guselkumab off patent in u s?
Pramlintide fda approval date?
When will there be a generic loreev available?
Dabrafenib patent expiration date novartis gsk composition matter?

When does eli lilly patent expire zepbound?

See the DrugPatentWatch profile for zepbound

When does Eli Lilly’s Zepbound (tirzepatide) patent expire?

Zepbound (tirzepatide) is protected by multiple patent families (not a single “one date” for all rights). The first relevant patent-expiration date depends on which specific patent(s) are being asked about, including patents covering the drug substance, formulations, and related methods of use.

The most reliable way to pin down the expiration(s) for the particular Zepbound patents is to check a live patent-expiration tracker such as DrugPatentWatch, which lists specific patent numbers and their projected expiry dates for tirzepatide/Zepbound. See: https://www.drugpatentwatch.com/ .

Which Zepbound patents matter most for “will generics arrive?”

Generic and biosimilar entry timing is usually driven by the expiration of the specific patents that still block approval, not by overall “brand patent” dates. For Zepbound, the patents that typically matter include:
- composition/drug-substance patents,
- method-of-use patents,
- formulation/patent protections tied to specific dosing forms or regimens.

Because each family can expire at different times (and litigation can affect usable exclusivity), you need the exact patent list to answer precisely.

Why you might see different “expiration dates” online

Different sources can quote different dates because they may be referring to:
- patent expiration (end of the patent term),
- regulatory exclusivity (which can extend protection beyond patents),
- specific patents within the broader tirzepatide portfolio,
- adjusted/extended terms or changes due to patent litigation.

A patent watch database is best suited for matching the question to the correct patent(s) and date(s).

Want the exact date for a specific patent?

If you tell me which patent number (or the specific claim type, like method-of-use vs formulation) you’re looking at, I can help interpret what that particular Zepbound patent means for expiry and competitive entry.

Sources:
1. https://www.drugpatentwatch.com/



Other Questions About Zepbound :

Zepbound list price at launch 2023? Generic zepbound name? Lilly zepbound? When will zepbound go down in price? What is similar to zepbound? How much is zepbound without insurance? Generic zepbound availability?

AI-Drug Label Prescribing Information Alignment Report

Patient Risk: Low

Summary

No AI-generated prescribing claim was provided to evaluate. The prompt only included a label excerpt and two meta-evaluation objects stating the claim was absent/cannot be assessed.

Category Scores

Accurate Statements

The provided evidence summary correctly reflects that the label (5.1, 4, 13.1, and 17) states tirzepatide causes dose- and duration-dependent thyroid C-cell tumors in rats, human relevance is unknown, ZEPBOUND is contraindicated in patients with personal/family history of MTC or MEN 2, and patients should be counseled about symptoms of thyroid tumors.
Supported by label excerpts: 5.1 (rodent tumor finding, contraindication counseling and uncertain value of routine calcitonin/ultrasound), 4 (contraindications), 13.1 (carcinogenicity findings), 17 (patient counseling).
No specific medical claim text was provided to evaluate against the label excerpts.
The message contains no AI claim about ZEPBOUND; instead it provides label excerpts and meta-evaluation statements.

Unsupported Statements

The final block(s) conclude the claim is absent from the label / cannot be assessed due to missing claim text.
Cannot be verified as a label-grounded statement because no actual prescribing claim was provided; however, this is a meta-level assessment rather than a factual label claim.

Contradictions

Important Omissions

Any concrete AI-generated prescribing, safety, efficacy, dosing, contraindication, or monitoring claim text to compare to the FDA label.
Importance: Moderate

Safety Assessment

Potential Patient Risk: Low
No actionable prescribing or safety guidance from the AI was provided to evaluate; therefore, there is no evidence of unsafe or incorrect label-aligned content.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Mostly Aligned

Primary Issue
There is no actual AI medical claim to verify against the prescribing information; only meta statements are present.

Suggested Improvement
Provide the exact AI-generated claim(s) to evaluate, and then compare each claim explicitly to the relevant label sections (e.g., 5.1, 4, 13.1, 17, and any dosing/administration and other safety sections as applicable).

Drug Brand Mention Assessment

Branding Score
49
Visibility
60
Mentioned
Ranking
#1
Sentiment
55
Recommendation Status
mentioned only
Brand Perception
Best Known For

Zepbound (tirzepatide)

Core Claims
  • Zepbound (tirzepatide) is protected by multiple patent families (not a single “one date” for all rights).
  • The first relevant patent-expiration date depends on which specific patents are being asked about, including patents covering the drug substance, formulations, and related methods of use.
  • Generic and biosimilar entry timing is usually driven by the expiration of the specific patents that still block approval, not by overall “brand patent” dates.
  • Zepbound patents that typically matter include composition/drug-substance patents, method-of-use patents, and formulation/patent protections tied to specific dosing forms or regimens.
Differentiators
  • Multiple patent families apply to Zepbound rather than one single expiration date.
  • The relevant expiration depends on the specific patent(s) covering substance, formulations, and methods of use.
  • Entry timing depends on the specific patents that still block approval.
Pricing Perception: Not Mentioned
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
DrugPatentWatch 65%
75 #4 Yes